Bionano Genom (BNGO)

$3.06 0.03 (0.98%)

20:00 EDT BNGO Stock Quote Delayed 30 Minutes

Hold On to Bionano Genomics Stock Until It Reaches $6 at Least

By David Moadel, InvestorPlace Contributor Mar 8, 2022

One analyst is modeling significant upside for BNGO stock, and there's financial data to suggest that a 3x move is entirely possible.

Bionano Genomics Has Attractive Applications But An Unattractive Stock Price

Bionano Stock Looks to Have a Monster Comeback in Its Future

Investors Have Cast Their ‘No’ Votes Against Bionano Genomics

Volume:

Previous Close $3.36

Market Cap 9.11M

PE Ratio -0.05

EPS -64.7156

Volume (Avg. Vol.) 90,669

Day's Range $2.99 - $3.24

52-Week Range $2.68 - $72.60

Dividend & Yield N/A (N/A)

BNGO Stock Predictions, Articles, and Bionano Genom News

Bionano Is Not the Genomics Stock To Bet On

By Muslim Farooque, InvestorPlace Contributor Feb 4, 2022

Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.

Bionano Genomics Is Interesting as Genome Testing Scales Upwards

By Alex Sirois, InvestorPlace Contributor Jan 25, 2022

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing.

7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now

By Larry Ramer, InvestorPlace Contributor Jan 6, 2022

These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds.

Bionano Genomics Stock Is a Low-Priced Bet on Sound Science

By Louis Navellier and the InvestorPlace Research Staff Jan 3, 2022

Even though BNGO stock investors struggled in 2021, prepare for new price discovery as Bionano pushes the envelope in optical genome mapping.

The Critics Are Wrong About Bionano Stock

By Larry Ramer, InvestorPlace Contributor Dec 27, 2021

The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors.

This Analyst’s Saphyr Calculations Suggest Buying Bionano While It’s Down

By Louis Navellier and the InvestorPlace Research Staff Dec 14, 2021

If BNGO stock reaches Oppenheimer’s price target, investors are looking at a return of more than 300%, plus long-term growth potential.

Bionano Genomics Proves Not Everything Genetic is Gold

By Dana Blankenhorn, InvestorPlace Contributor Dec 1, 2021

Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.

Wait for Bionano Stock to Fall Further Before Buying

By Joseph Nograles Nov 23, 2021

BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term.

Bionano’s Is on Track for Growth Thanks to Saphyr

By Louis Navellier and the InvestorPlace Research Staff Nov 19, 2021

BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play.

With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here

By Larry Ramer, InvestorPlace Contributor Nov 12, 2021

Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.

Bionano Genomics Is Still Set to Pay Off Big for Patient Investors

By Louis Navellier and the InvestorPlace Research Staff Oct 28, 2021

It may take time for it to potentially move back to its all-time high of $15.69 per share. But given that's nearly triple what it trades today, patience could pay off big with BNGO stock.

Bionano Genomics’ Latest Software Business Acquisition Adds Immense Value

By Louis Navellier and the InvestorPlace Research Staff Oct 19, 2021

BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche.

Bionano Genomics Stock Looks Ready to Reward Patient Investors

By Chris Markoch, InvestorPlace Contributor Oct 18, 2021

BNGO stock is down 25% since the beginning of the year. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded.